Tachycardia, Atrioventricular Nodal Reentry Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 13, 2026 · Data accessed through Patsnap Life Sciences MCP servers.

This Tachycardia, Atrioventricular Nodal Reentry Indication Strategy Report ranks the opportunity using disease burden, biological rationale, unmet need, competitive intensity and transaction signals. It is designed for biopharma portfolio, search-and-evaluation, licensing and translational teams. The analysis focuses exclusively on Tachycardia, Atrioventricular Nodal Reentry; adjacent diseases are mentioned only when needed to interpret evidence or trial design.

Executive assessment

Tachycardia, Atrioventricular Nodal Reentry receives an overall strategic score of 70/100. The opportunity combines an unmet-need score of 85/100, competition score of 61/100 and market-attractiveness score of 75/100. Scores are directional decision aids, not forecasts: they synthesize the MCP evidence returned on the access date and explicitly penalize crowded development landscapes.

Disease background and strategic definition

Abnormally rapid heartbeats caused by reentry of atrial impulse into the dual (fast and slow) pathways of ATRIOVENTRICULAR NODE. The common type involves a blocked atrial impulse in the slow pathway which reenters the fast pathway in a retrograde direction and simultaneously conducts to the atria and the ventricles leading to rapid HEART RATE of 150-250 beats per minute.

For indication strategy, the disease label is only the starting point. A credible target product profile should specify the treatable population, diagnostic pathway, severity threshold, prior-therapy requirements, measurable clinical outcomes and treatment setting. In Tachycardia, Atrioventricular Nodal Reentry, value creation will depend on selecting a phenotype that is biologically coherent and commercially reachable, while avoiding a trial population so narrow that recruitment and launch become impractical.

The disease record is identified by Patsnap disease ID 30002de0b3454290b23766b9bf878a9c and MeSH identifier D013611. These identifiers help keep searches reproducible when synonyms or spelling variants change.

Epidemiology and disease-burden evidence

Evidence signal 1: Heart Disease and Stroke Statistics—2021 Update

• Atrioventricular reentrant tachycardia prevalence decreases with age, whereas atrioventricular nodal reentrant tachycardia and atrial tachycardia preva- lences increase with advancing age.46 • The majority of patients with atrioventricular reen- trant tachycardia were males (55%), whereas females constituted the majority with atrioven- tricular nodal reentrant tachycardia (70%) or atrial tachycardia (62%) in the study by Porter et al.46 • Multifocal atrial tachycardia is an arrhythmia that is commonly confused with AF and is character- ized by 3 distinct P-wave morphologies, irregular R-R intervals, and a rate >100 beats per minute. It is uncommon in both children48 and adults,49 with a prevalence in hospitalized adults estimated at 0.05% to 0.32%.49 The average age at onset in adults is 72 years. Adults with multifocal atrial tachycardia have a high mortality rate, with esti- mates around 45%, but this is generally ascribed to the underlying condition(s).49 In a study of older ambulatory adults in Greece, the mortality in fol- low-up did not differ by whether multifocal atrial rhythms were detected on baseline ECG.50 WPW Syndrome Prevalence • A WPW electrocardiographic pattern was observed in 0.11% of males and 0.04% of females among 47 358 ECGs from adults participating in 4 large Belgian epidemiological studies.51 In an ECG study of 32 837 Japanese students, a WPW elec- trocardiographic pattern was reported in 0.07%, 0.07%, and 0.17% of elementary, junior high, and high school students, respectively.52 Complications

Review the underlying epidemiology source

Evidence signal 2: Heart Disease and Stroke Statistics—2023 Update Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

• The majority of patients with atrioventricular reen- trant tachycardia were males (55%), whereas females constituted the majority with atrioven- tricular nodal reentrant tachycardia (70%) or atrial tachycardia (62%) in a series of 1754 individuals undergoing catheter ablation.44 • Multifocal atrial tachycardia is an arrhythmia that may be confused with AF and is characterized by ≥3 distinct P-wave morphologies, irregular R-R intervals, and a ventricular rate >100 bpm. It usu- ally occurs as a complication of acute severe illness such as sepsis or acute pulmonary conditions. It is uncommon in both children46 and adults,47 with a prevalence in hospitalized adults estimated at 0.05% to 0.32%.47 The average age at onset in adults is 72 years. Adults with multifocal atrial tachy- cardia have a high mortality rate, with estimates of ≈45%, but this is generally ascribed to the under- lying condition(s).47 In a study of older ambulatory adults in Greece, the mortality in follow-up did not differ by the presence of multifocal atrial rhythms on baseline ECG.48 WPW Syndrome Prevalence • WPW syndrome refers to the presence of ventricu- lar preexcitation on the ECG combined with related arrhythmia (SVT). A WPW electrocardiographic pattern (ventricular preexcitation) was observed in 0.11% of males and 0.04% of females among 47 358 ECGs from adults participating in 4 large Belgian epidemiological studies.49 In an electro- cardiographic study of 32 837 Japanese students, ventricular preexcitation was reported in 0.07%, 0.07%, and 0.17% of elementary, junior high, and high school students

Review the underlying epidemiology source

Evidence signal 3: Heart Disease and Stroke Statistics—2020 Update Heart Disease and Stroke Statistics— 2020 Update

• In a US-based national pediatric electrophysiology registry study, AV reentrant tachycardia was the most common SVT mechanism (68%), whereas the remainder of the patients had AV nodal reen- trant tachycardia (32%).50 • AV reentrant tachycardia prevalence decreases with age, whereas AV nodal reentrant tachycar- dia and atrial tachycardia prevalence increase with advancing age.49 • The majority of patients with AV reentrant tachy- cardia were males (55%), whereas females con- stituted the majority with AV nodal reentrant tachycardia (70%) or atrial tachycardia (62%) in the study by Porter et al.49 • Multifocal atrial tachycardia is an arrhythmia that is commonly confused with AF and is character- ized by 3 distinct P-wave morphologies, irregular R-R intervals, and a rate >100 beats per minute. It is uncommon in both children51 and adults,52 with a prevalence in hospitalized adults estimated at 0.05% to 0.32%.52 The average age of onset in adults is 72 years. Adults with multifocal atrial tachycardia have a high mortality rate, with esti- mates around 45%, but this is generally ascribed to the underlying condition(s).52 In a study of older ambulatory adults in Greece, the mortality in fol- low-up did not differ by whether or not multifocal atrial rhythms were detected on baseline ECG.53 WPW Syndrome Prevalence • A WPW electrocardiographic pattern was observed in 0.11% of males and 0.04% of females among 47 358 ECGs from adults participating in 4 large Belgian epidemiological studies.54 In a study of 32 837 Japanese students who were required by law to receive ECGs before ent

Review the underlying epidemiology source

Epidemiology must be translated into an addressable population rather than copied into a revenue model. The recommended funnel is total prevalent or incident population → diagnosed population → clinically eligible segment → treated population → realistically accessible population. Analysts should separate point prevalence from lifetime prevalence, distinguish incidence from diagnosis rates, and avoid combining incompatible geographies or age bands.

For Tachycardia, Atrioventricular Nodal Reentry, the highest-value next epidemiology work is to quantify diagnostic delay, severity distribution, current treatment penetration and the proportion managed in specialist centers. Those variables often move the commercial case more than a single headline prevalence statistic.

Unmet need and patient-value thesis

Unmet need in Tachycardia, Atrioventricular Nodal Reentry should be framed as a measurable gap: inadequate disease control, treatment-limiting toxicity, burdensome administration, irreversible progression, delayed diagnosis, weak durability or lack of options for a defined subgroup. A program is strategically attractive when its mechanism can plausibly change one of those outcomes and when the clinical endpoint is accepted by regulators, physicians and payers.

The strongest development thesis would connect mechanism to a pre-specified responder population, demonstrate a clinically interpretable benefit, and reduce a meaningful part of the care burden. A weak thesis would rely only on statistical significance, use an endpoint disconnected from daily function, or assume that rarity automatically supports premium pricing.

Target mechanism: hERG

Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Channel properties are modulated by cAMP and subunit assembly (PubMed:10837251). Characterized by unusual gating kinetics by producing relatively small outward currents during membrane depolarization and large inward currents during subsequent repolarization which reflect a rapid inactivation during depolarization and quick recovery from inactivation but slow deactivation (closing) during repolarization (PubMed:10219239, PubMed:10753933, PubMed:10790218, PubMed:10837251, PubMed:11997281, PubMed:12063277, PubMed:18559421, PubMed:22314138, PubMed:22359612, PubMed:26363003, PubMed:27916661, PubMed:9230439, PubMed:9351446, PubMed:9765245). Forms a stable complex with KCNE1 or KCNE2, and that this heteromultimerization regulates inward rectifier potassium channel activity (PubMed:10219239, PubMed:9230439). Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation. Has no inward rectifier potassium channel activity by itself, but modulates channel characteristics by forming heterotetramers with other isoforms which are retained intracellularly and undergo ubiquitin-dependent degradation.

The proposed mechanism anchor for this landscape is KCNH2. Target selection does not imply that every Tachycardia, Atrioventricular Nodal Reentry patient is target-dependent. The translational package should establish expression or pathway activity in the intended tissue, human genetic or biomarker support, pharmacodynamic tractability, a therapeutic window and evidence that target modulation changes disease-relevant biology.

Critical de-risking experiments include orthogonal target engagement assays, dose–response work in disease-relevant models, biomarker qualification, assessment of compensatory pathways and explicit off-target safety testing. Human evidence should be weighted above model-only evidence, and negative clinical results in related mechanisms should be treated as learning assets rather than ignored.

Clinical development and competitive landscape

The MCP search returned 41 matched registered studies overall. The most recent records sampled for this report are:

• NCT07630480 — 3D Mapping Versus Conventional Ablation in AVNRT (MAP-AVNRT); status: Completed; phase: Not Applicable; sponsor(s): Kafrelsheikh University; enrollment: 80.
• NCT07617077 — NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia (NASVAL-SVT); status: Recruiting; phase: Not Applicable; sponsor(s): not stated; enrollment: 60.
• NCT07456423 — Adenosine vs. Diltiazem (AVNRTstdy); status: Completed; phase: Phase 4; sponsor(s): not stated; enrollment: 140.

Raw trial count is not the same as commercial competition. Each program should be normalized by phase, modality, mechanism, sponsor strength, recruitment status, geography and the exact patient segment. Observational or investigator-led studies may reveal endpoint conventions and recruitment networks without representing product competition; discontinued assets may still expose safety or efficacy risks.

A differentiated Tachycardia, Atrioventricular Nodal Reentry program should define its advantage against the standard of care and the likely future standard at launch, not merely today's comparator. Useful whitespace can come from earlier intervention, a biomarker-selected subgroup, superior durability, safer chronic use, simpler delivery or a combination strategy with a clear contribution from each component.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned for Tachycardia, Atrioventricular Nodal Reentry. This is decision-relevant negative evidence: the indication may be under-transacted, may trade through broader disease labels, or may require target- and asset-level deal searches. It should not be interpreted as proof of zero partnering activity.

Transaction evidence should be interpreted alongside asset quality. Headline values may include contingent milestones, broad platform rights, multiple indications or undisclosed options. A defensible comparable set therefore requires matching disease, target, modality, development phase, territory and deal structure. Where direct comparables are sparse, triangulation across target-level and therapeutic-area transactions is preferable to forcing an unrelated deal into the valuation.

Potential partners will expect a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical development plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Early outreach is most productive when the program has a clear upcoming catalyst and a credible explanation of why the asset can win specifically in Tachycardia, Atrioventricular Nodal Reentry.

Market attractiveness and access considerations

The market opportunity is shaped by more than patient count. Diagnosis infrastructure, concentration of prescribers, treatment duration, administration setting, payer controls, competing generics, monitoring requirements and geographic reimbursement all influence attainable value. For Tachycardia, Atrioventricular Nodal Reentry, a launch model should test conservative, base and upside scenarios rather than assume uniform diagnosis and treatment.

Pricing power will depend on magnitude and durability of benefit, evidence quality, alternatives and budget impact. Developers should begin payer research before pivotal design so that endpoints, comparators and follow-up duration support both regulatory approval and reimbursement. Evidence generation should include health-resource use, quality of life and treatment burden when those are central to the value proposition.

Risks, evidence gaps and decision gates

• Disease-definition risk: validate that the proposed population is consistently diagnosed and recruitable.
• Biology risk: demonstrate that KCNH2 is causal or therapeutically relevant in the intended subgroup.
• Translation risk: link target engagement to a biomarker and a clinically meaningful endpoint.
• Competition risk: refresh the landscape before each investment gate and include mechanisms likely to launch first.
• Commercial risk: test diagnosis, access, pricing and adoption assumptions with physicians and payers.
• Data risk: treat zero-result searches as prompts for synonym and roll-up analysis, not definitive absence.

The recommended decision gates are: confirm epidemiology and segmentation; validate target biology in human evidence; establish a differentiated target product profile; obtain early clinical proof of mechanism; and only then scale investment toward registrational development or partnering. Each gate should have pre-agreed stop criteria.

Strategic recommendation

Tachycardia, Atrioventricular Nodal Reentry merits continued evaluation with an evidence-led, milestone-based strategy. The current signal supports prioritizing a narrowly defined population where KCNH2 biology can be measured and where the clinical benefit would be meaningful relative to available care. The program should advance only if follow-up work confirms population size, mechanistic coherence, endpoint feasibility and a credible route to differentiation.

For business development, the near-term goal is not to maximize the number of outreach targets; it is to assemble a partner-ready thesis that explains the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scores in this report provide a common language for comparing the opportunity while preserving the underlying evidence and uncertainties.

Methodology and source note

This report was assembled on August 13, 2026 using Patsnap MCP tools in a reproducible sequence: disease profile retrieval, epidemiology semantic search, target profile retrieval, clinical-trial search and pharmaceutical-deal search. Results reflect the returned records and query scope on that date. Counts may change as databases update, and the analysis is not medical, regulatory or investment advice.

The ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Qualitative judgments are informed by disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Readers should rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio decision.

Conclusion

Tachycardia, Atrioventricular Nodal Reentry offers a tractable strategic question: can a biologically grounded program deliver a material patient benefit in a clearly identifiable population and do so with sufficient differentiation to earn adoption? The evidence assembled here gives teams a starting map, while the identified gaps define the next diligence plan. Use the linked MCP marketplace to refresh the evidence as programs, trials and transactions evolve.